Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
| Revenue (TTM) | $450.91M |
| Gross Profit (TTM) | $417.28M |
| EBITDA | $169.77M |
| Operating Margin | 49.80% |
| Return on Equity | 131.80% |
| Return on Assets | 27.00% |
| Revenue/Share (TTM) | $5.15 |
| Book Value | $2.19 |
| Price-to-Book | 30.96 |
| Price-to-Sales (TTM) | 6.82 |
| EV/Revenue | 13.17 |
| EV/EBITDA | 33.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1843.00% |
| Shares Outstanding | $89.51M |
| Float | $65.22M |
| % Insiders | 9.21% |
| % Institutions | 81.86% |
Volatility is currently expanding
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.
A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations
LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Liquidia (LQDA) To Contact Him Directly To Discuss Their Options
LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LQDA and any ticker you trade — then tracks every position and per-strategy win rate.
